Notice: unserialize(): Error at offset 2753 of 5598 bytes in /data/html/www_bioworld_com/includes/ on line 559 Pharma: Clinic Roundup | BioWorld

Login to Your Account

Pharma: Clinic Roundup

Tuesday, March 13, 2012
• Pfizer Inc., of New York, said data from a Phase III study of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) met all endpoints, showing immunogenicity and establishing a safety profile in children and adolescents, ages 5 through 17.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription